Warner Pharmaceuticals: Metformin and Empagliflozin Tablets (V) Receive Drug Registration Certificate

2026-03-26 05:55:52

People’s Financial News, March 24 — Warner Pharmaceutical (688799) announced on March 24 that it recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration for Metformin and Empagliflozin Tablets (V). These tablets, combined with diet control and exercise, are suitable for adult patients with type 2 diabetes who are being treated with empagliflozin and metformin hydrochloride to improve their blood sugar control. The company’s Metformin and Empagliflozin Tablets (V) obtained drug registration approval under the new classification of chemical drugs category 4, which is considered to have passed the consistency evaluation.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.